EUVIMEDEUVIMED entdecken
Crossref

Eye‐Drop Nano‐Formulation of Catalase Self‐Assembled with Thiolated Chitosan for Effective Treatment of Dry Eye Disease

Ming Shao, Yu Chai, Yutong Jiang, Xinyi Wu, Wenjie Xie, Jiayi Lu, Xuehui Fu, Yao He, Xiaofeng Zhang, Han Zhang, Zhuang Liu iD

Advanced Materials · 2025-05 · 37 (19)

DOI: 10.1002/adma.202415353 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 23.03.2025. Verfasst von Ming Shao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Soochow University, S…. Hauptthemen laut MEDLINE: Chitosan, Dry Eye Syndromes, Catalase, Nanoparticles. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Suzhou Medical Innovation Application Research Project, Suzhou Key Laboratory of Nanotechnology and Biomedicine, Collaborative Innovation Center of Suzhou Nano Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dry eye disease (DED), the most prevalent ophthalmological condition worldwide, can cause severe ocular discomfort and even visual impairment. Effective yet safe therapeutics for severe DED are still highly demanded. Herein, considering the important role of excessive reactive oxygen species (ROS) in triggering DED, an eye‐drop nano‐formulation of catalase (CAT) self‐assembled with cysteine‐modified chitosan (CS‐Cys) is designed for DED treatment. Upon eye‐drop administration of CS‐Cys/CAT nanoparticles, CS‐Cys can form disulfide bonds with abundant thiols in the mucin layer of the tear film, anchoring catalase to the corneal surface. Thus the excess ROS accumulated on the ocular surface can be effectively eliminated, resulting in a regulated tear microenvironment. In mouse and rabbit models, it is verified that CS‐Cys/CAT eye drops can offer excellent therapeutic effects, especially in promoting the recovery of damaged epithelium and increasing tear secretion. Remarkably, CS‐Cys/CAT eye drops showed notably better therapeutic performance than clinically used cyclosporin and dexamethasone, as well as several new DED drugs in clinical trials. Thus, the work presents a unique nanoparticulate eye‐drop‐based ocular delivery system to allow prolonged ocular retention of protein therapeutics, and such nanoformulation formulated by fully biocompatible/biodegradable components possesses significant translational potential for effective and safe DED treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChitosanDry Eye SyndromesCatalaseNanoparticlesOphthalmic SolutionsSulfhydryl CompoundsAnimalsRabbitsMiceTearsReactive Oxygen SpeciesHumans

Stichwörter der Autor:innen

anti‐oxidant therapycatalasedry eye diseaseprecorneal retentionthiolated chitosan

Substanzen

ChitosanCatalaseOphthalmic SolutionsSulfhydryl CompoundsReactive Oxygen Species

Autor:innen und Institutionen

  • Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials & Devices, Soochow University, Suzhou, 215123, China.
  • InnoBM Pharmaceuticals Co. Ltd., Suzhou, 215123, China.
  • Department of Ophthalmology, The Fourth Affiliated Hospital of Soochow University, Suzhou, 215123, China.
  • College of Pharmaceutical Science, Soochow University, Suzhou, Jiangsu, 215123, China.
  • Macao Institute of Materials Science and Engineering, Macau University of Science and Technology, Taipa, 999078, China.

ORCID-Profile: Zhuang Liu

Förderung

  • Suzhou Medical Innovation Application Research Project
  • Suzhou Key Laboratory of Nanotechnology and Biomedicine
  • Collaborative Innovation Center of Suzhou Nano Science and Technology
  • New Cornerstone Science Foundation
  • Agência Regional para o Desenvolvimento da Investigação, Tecnologia e Inovação
  • National Natural Science Foundation of China
  • National Center of Technology Innovation for Biopharmaceuticals
  • Jiangsu Key R&D Program (Social Development) Project

Zitieren

APA

Shao, M., Chai, Y., Jiang, Y., Wu, X., Xie, W., Lu, J., Fu, X., He, Y., Zhang, X., Zhang, H., & Liu, Z. (2025). Eye‐Drop Nano‐Formulation of Catalase Self‐Assembled with Thiolated Chitosan for Effective Treatment of Dry Eye Disease. Advanced Materials, 37(19). https://doi.org/10.1002/adma.202415353

Vancouver

Shao M, Chai Y, Jiang Y, Wu X, Xie W, Lu J, et al. Eye‐Drop Nano‐Formulation of Catalase Self‐Assembled with Thiolated Chitosan for Effective Treatment of Dry Eye Disease. Advanced Materials. 2025;37(19). doi:10.1002/adma.202415353

BibTeX
@article{Shao2025,
  author = {Shao, Ming and Chai, Yu and Jiang, Yutong and Wu, Xinyi and Xie, Wenjie and Lu, Jiayi and Fu, Xuehui and He, Yao and Zhang, Xiaofeng and Zhang, Han and Liu, Zhuang},
  title = {Eye‐Drop Nano‐Formulation of Catalase Self‐Assembled with Thiolated Chitosan for Effective Treatment of Dry Eye Disease},
  journal = {Advanced Materials},
  year = {2025},
  volume = {37},
  number = {19},
  doi = {10.1002/adma.202415353}
}
Kostenlos starten →